New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Enspryng lowered relapse severity in double-blind periods of SAkura Phase III studies (SAkuraSky, SAkuraStar). Pooled data from SAkura open-label extension...







